null Donald Vinh, MD, FRCPC, FACP

Scientist, RI-MUHC, Glen site

Infectious Diseases and Immunity in Global Health Program

Centre for Translational Biology

Associate Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Infectious Diseases, MUHC



primary (genetic) immunodeficiencies • molecular genetics • translational research • immunity • infections

Research Focus

My research focuses on identifying how genetic defects of immunity predispose patients to infectious diseases. A fundamental enigma in the field of infectious diseases is the variability in clinical outcomes between individuals exposed to the same microbial environment. For a given microbe, what distinguishes those who are “well” or “mildly symptomatic” from those who develop “life-threatening disease”? Accumulating evidence demonstrates that mutations in critical genes can cause a variety of immunodeficiencies, resulting in human susceptibility to specific infectious diseases. My research program is distinguished by the unique ability to bring patients (and relevant family members) with unusual, severe or recalcitrant infections into the laboratory and meticulously study them, through state-of-the-art genomic and functional immunologic studies and model systems, to delineate fundamental principles of human immunobiology. In so doing, we aim to translate our findings into innovative therapies directly relevant for patients, and to discover novel diseases of human immunity.

Research initiatives
MUHC COVID-19 Biobank
COVID Human Genetic Effort
The COVID-19 and Cancer Consortium (CCC19)
Genetic Disorders of Mucociliary Clearance Consortium (GDMCC)

Selected Publications

Click on Pubmed to see my current publications list

  • Vinh DC, Gouin JP, Cruz-Santiago D, Canac-Marquis M, Bernier S, Bobeuf F, Sengupta A, Brassard JP, Guerra A, Dziarmaga R, Perez A, Sun Y, Li Y, Roussel L, Langelier MJ, Ke D, Arnold C, Whelan M, Pelchat M, Langlois MA, Zhang X, Mazer BD; COVID-19 Immunity Task Force and UNCoVER Investigators. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Lancet Healthy Longev. 2022 Feb 23. doi: 10.1016/S2666-7568(22)00012-5. Epub ahead of print. PMID: 35224524.

  • Cheng AP, Cheng MP, Gu W, Sesing Lenz J, Hsu E, Schurr E, Bourque G, Bourgey M, Ritz J, Marty FM, Chiu CY, Vinh DC, De Vlaminck I. Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med (N Y). 2021 Apr 9;2(4):411-422.e5. doi: 10.1016/j.medj.2021.01.001. Epub 2021 Jan 16. PMID: 33521749.

  • Golizeh M, Winter K, Roussel L, Landekic M, Langelier M, Loo VG, Ndao M, Vinh DC. Fecal host biomarkers predicting severity of Clostridioides difficile infection. JCI Insight. 2021 Jan 11;6(1):e142976. doi: 10.1172/jci.insight.142976. PMID: 33232301.

  • Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Béziat V, Manry J, Shaw E, Haljasmägi L, Peterson P, Lorenzo L, Bizien L, Trouillet-Assant S, Dobbs K, de Jesus AA, Belot A, Kallaste A, Catherinot E, Tandjaoui-Lambiotte Y, Le Pen J, Kerner G, Bigio B, Seeleuthner Y, Yang R, Bolze A, Spaan AN, Delmonte OM, Abers MS, Aiuti A, Casari G, Lampasona V, Piemonti L, Ciceri F, Bilguvar K, Lifton RP, Vasse M, Smadja DM, Migaud M, Hadjadj J, Terrier B, Duffy D, Quintana-Murci L, van de Beek D, Roussel L, Vinh DC, Tangye SG, Haerynck F, Dalmau D, Martinez-Picado J, Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodríguez-Gallego C, Vogt G, Mogensen TH, Oler AJ, Gu J, Burbelo PD, Cohen JI, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Rossignol P, Mayaux J, Rieux-Laucat F, Husebye ES, Fusco F, Ursini MV, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Castagnoli R, Montagna D, Licari A, Marseglia GL, Duval X, Ghosn J; HGID Lab; NIAID-USUHS Immune Response to COVID Group; COVID Clinicians; COVID-STORM Clinicians; Imagine COVID Group; French COVID Cohort Study Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort, Tsang JS, Goldbach-Mansky R, Kisand K, Lionakis MS, Puel A, Zhang SY, Holland SM, Gorochov G, Jouanguy E, Rice CM, Cobat A, Notarangelo LD, Abel L, Su HC, Casanova JL. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct 23;370(6515):eabd4585. doi: 10.1126/science.abd4585. Epub 2020 Sep 24. PMID: 32972996.

  • Roussel L, Landekic M, Golizeh M, Gavino C, Zhong MC, Chen J, Faubert D, Blanchet-Cohen A, Dansereau L, Parent MA, Marin S, Luo J, Le C, Ford BR, Langelier M, King IL, Divangahi M, Foulkes WD, Veillette A, Vinh DC. Loss of human ICOSL results in combined immunodeficiency. J Exp Med. 2018 Dec 3;215(12):3151-3164. doi: 10.1084/jem.20180668. PMID: 30498080.